Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
29 hedge funds and large institutions have $3.52M invested in Vyant Bio, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 12 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
28% less funds holding
Funds holding: 40 → 29 (-11)
40% less capital invested
Capital invested by funds: $5.84M → $3.52M (-$2.33M)
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QGM
Quality Growth Management
Rancho Santa Fe,
California
|
+$75.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.9K |
| 3 |
EGA
Eagle Global Advisors
Houston,
Texas
|
+$50.1K |
| 4 |
SCA
Stonebridge Capital Advisors
St Paul,
Minnesota
|
+$49.8K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$44.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
-$588K |
| 2 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$456K |
| 3 |
Renaissance Technologies
New York
|
-$214K |
| 4 |
Millennium Management
New York
|
-$193K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$108K |
VYNT Hedge Fund Activity: Q1 2016 in Review
29 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q1 2016, worth a combined $3.52M — down 40% from $5.84M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of VYNT and 1 opened new positions — a net loss of 11 holders — while 6 trimmed existing stakes and 10 added.
The largest buyer was Quality Growth Management, adding an estimated $75.2K. The largest seller was Millrace Asset Group, exiting entirely with an estimated $588K sold.
- 29 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q1 2016, down from 40 in Q4 2015.
- Funds reported $3.52M of Vyant Bio, Inc. Common Stock stock for Q1 2016, down 40% quarter-over-quarter.
- 1 fund opened new Vyant Bio, Inc. Common Stock positions in Q1 2016 and 12 closed out, a net change of -11 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q1 2016 was Quality Growth Management, an estimated $75.2K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q1 2016 was Millrace Asset Group, an estimated $588K sold.
Based on aggregated 13F filings for Q1 2016.